Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.

MLA

Weiss, Tracey, et al. “Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.” Patient Preference and Adherence, vol. 14, Nov. 2020, pp. 2337–45. EBSCOhost, https://doi.org/10.2147/PPA.S277676.

APA

Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020). Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Patient Preference and Adherence, 14, 2337–2345. https://doi.org/10.2147/PPA.S277676

Chicago

Weiss, Tracey, Richard D Carr, Sampriti Pal, Lingfeng Yang, Baanie Sawhney, Robert Boggs, Swapnil Rajpathak, and Kristy Iglay. 2020. “Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.” Patient Preference and Adherence 14 (November): 2337–45. doi:10.2147/PPA.S277676.